HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Waldenstrom Macroglobulinemia
Related studies linked through entity extraction aliases.
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
- Status
- RECRUITING
- Phase
- PHASE2
Spanish Registry of Patients With IgM Monoclonal Gammopathies
- Status
- RECRUITING
- Phase
- N/A
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
- Status
- RECRUITING
- Phase
- NA
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
- Status
- RECRUITING
- Phase
- NA
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
- Status
- COMPLETED
- Phase
- N/A
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Status
- RECRUITING
- Phase
- PHASE1
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
- Status
- WITHDRAWN
- Phase
- PHASE2
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
- Status
- COMPLETED
- Phase
- PHASE1
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib + Venetoclax in Untreated WM
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2